Cargando…

Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial

Many patients with obsessive-compulsive disorder (OCD) do not receive cognitive behavioral therapy with exposure and response prevention (first line treatment for OCD), for example, due to patients’ fear of the exposure and reservations of the therapists. Technology-supported exposure (e.g., exposur...

Descripción completa

Detalles Bibliográficos
Autores principales: Lohse, Luzie, Jelinek, Lena, Moritz, Steffen, Blömer, Jannik, Bücker, Lara, Miegel, Franziska
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100604/
https://www.ncbi.nlm.nih.gov/pubmed/37055854
http://dx.doi.org/10.1186/s40359-023-01116-3
_version_ 1785025312861454336
author Lohse, Luzie
Jelinek, Lena
Moritz, Steffen
Blömer, Jannik
Bücker, Lara
Miegel, Franziska
author_facet Lohse, Luzie
Jelinek, Lena
Moritz, Steffen
Blömer, Jannik
Bücker, Lara
Miegel, Franziska
author_sort Lohse, Luzie
collection PubMed
description Many patients with obsessive-compulsive disorder (OCD) do not receive cognitive behavioral therapy with exposure and response prevention (first line treatment for OCD), for example, due to patients’ fear of the exposure and reservations of the therapists. Technology-supported exposure (e.g., exposure therapy with response prevention in mixed reality [MERP]) for patients with OCD may help to overcome this obstacle. Building upon findings of our pilot study objectives of this study are to evaluate the efficacy, expectations of treatment success, feasibility, and acceptance of MERP as well as to identify possible limitations. In total, 64 outpatients with contamination-related OCD will be recruited and randomized to one of two conditions: MERP (six sessions in six weeks) and self-guided exposure therapy (six exercises in six weeks). Participants will be assessed before (baseline), after the six-week intervention period (post), as well as three months after post assessment (follow-up) regarding symptomatology (Yale-Brown Obsessive Compulsive Scale; Y-BOCS), their subjective evaluation of MERP (acceptance) and sense of presence. The planned study is the first to investigate MERP in patients with OCD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40359-023-01116-3.
format Online
Article
Text
id pubmed-10100604
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101006042023-04-14 Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial Lohse, Luzie Jelinek, Lena Moritz, Steffen Blömer, Jannik Bücker, Lara Miegel, Franziska BMC Psychol Study Protocol Many patients with obsessive-compulsive disorder (OCD) do not receive cognitive behavioral therapy with exposure and response prevention (first line treatment for OCD), for example, due to patients’ fear of the exposure and reservations of the therapists. Technology-supported exposure (e.g., exposure therapy with response prevention in mixed reality [MERP]) for patients with OCD may help to overcome this obstacle. Building upon findings of our pilot study objectives of this study are to evaluate the efficacy, expectations of treatment success, feasibility, and acceptance of MERP as well as to identify possible limitations. In total, 64 outpatients with contamination-related OCD will be recruited and randomized to one of two conditions: MERP (six sessions in six weeks) and self-guided exposure therapy (six exercises in six weeks). Participants will be assessed before (baseline), after the six-week intervention period (post), as well as three months after post assessment (follow-up) regarding symptomatology (Yale-Brown Obsessive Compulsive Scale; Y-BOCS), their subjective evaluation of MERP (acceptance) and sense of presence. The planned study is the first to investigate MERP in patients with OCD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40359-023-01116-3. BioMed Central 2023-04-13 /pmc/articles/PMC10100604/ /pubmed/37055854 http://dx.doi.org/10.1186/s40359-023-01116-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Lohse, Luzie
Jelinek, Lena
Moritz, Steffen
Blömer, Jannik
Bücker, Lara
Miegel, Franziska
Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
title Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
title_full Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
title_fullStr Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
title_full_unstemmed Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
title_short Efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
title_sort efficacy of exposure and response prevention therapy in mixed reality for patients with obsessive-compulsive disorder: study protocol for a randomized controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10100604/
https://www.ncbi.nlm.nih.gov/pubmed/37055854
http://dx.doi.org/10.1186/s40359-023-01116-3
work_keys_str_mv AT lohseluzie efficacyofexposureandresponsepreventiontherapyinmixedrealityforpatientswithobsessivecompulsivedisorderstudyprotocolforarandomizedcontrolledtrial
AT jelineklena efficacyofexposureandresponsepreventiontherapyinmixedrealityforpatientswithobsessivecompulsivedisorderstudyprotocolforarandomizedcontrolledtrial
AT moritzsteffen efficacyofexposureandresponsepreventiontherapyinmixedrealityforpatientswithobsessivecompulsivedisorderstudyprotocolforarandomizedcontrolledtrial
AT blomerjannik efficacyofexposureandresponsepreventiontherapyinmixedrealityforpatientswithobsessivecompulsivedisorderstudyprotocolforarandomizedcontrolledtrial
AT buckerlara efficacyofexposureandresponsepreventiontherapyinmixedrealityforpatientswithobsessivecompulsivedisorderstudyprotocolforarandomizedcontrolledtrial
AT miegelfranziska efficacyofexposureandresponsepreventiontherapyinmixedrealityforpatientswithobsessivecompulsivedisorderstudyprotocolforarandomizedcontrolledtrial